tradingkey.logo
tradingkey.logo

Arvinas Announces Positive Phase 1 Data For Arv-102 Showing Greater Than 50% Lrrk2 Degradation In The Csf Of Patients With Parkinson’S Disease Treated For 28 Days

ReutersMar 18, 2026 11:23 AM

- Arvinas Inc ARVN.O:

  • ARVINAS ANNOUNCES POSITIVE PHASE 1 DATA FOR ARV-102 SHOWING GREATER THAN 50% LRRK2 DEGRADATION IN THE CSF OF PATIENTS WITH PARKINSON’S DISEASE TREATED FOR 28 DAYS

  • ARVINAS INC - NO SERIOUS ADVERSE EVENTS, DISCONTINUATIONS, OR DEATHS REPORTED WITH ARV-102

  • ARVINAS INC: ARV-102 WAS WELL TOLERATED ACROSS ALL DOSE LEVELS FOLLOWING 28 DAYS OF ONCE-DAILY DOSING

  • ARVINAS INC - PLANS PHASE 1B TRIAL OF ARV-102 IN PSP IN Q2 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI